325 related articles for article (PubMed ID: 26592506)
1. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.
Erdmann E; Harding S; Lam H; Perez A
Diabetes Obes Metab; 2016 Mar; 18(3):266-73. PubMed ID: 26592506
[TBL] [Abstract][Full Text] [Related]
2. Observational follow-up of the PROactive study: a 6-year update.
Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
[TBL] [Abstract][Full Text] [Related]
3. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
[TBL] [Abstract][Full Text] [Related]
4. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).
Wilcox R; Bousser MG; Betteridge DJ; Schernthaner G; Pirags V; Kupfer S; Dormandy J;
Stroke; 2007 Mar; 38(3):865-73. PubMed ID: 17290029
[TBL] [Abstract][Full Text] [Related]
5. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
[TBL] [Abstract][Full Text] [Related]
6. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
Charbonnel B; Dormandy J; Erdmann E; Massi-Benedetti M; Skene A;
Diabetes Care; 2004 Jul; 27(7):1647-53. PubMed ID: 15220241
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).
Erdmann E; Charbonnel B; Wilcox RG; Skene AM; Massi-Benedetti M; Yates J; Tan M; Spanheimer R; Standl E; Dormandy JA;
Diabetes Care; 2007 Nov; 30(11):2773-8. PubMed ID: 17666462
[TBL] [Abstract][Full Text] [Related]
8. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
[TBL] [Abstract][Full Text] [Related]
9. [Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive Study and PERISCOPE Study].
Kawamori R
Nihon Rinsho; 2010 Feb; 68(2):235-41. PubMed ID: 20158090
[TBL] [Abstract][Full Text] [Related]
10. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
Wilcox R; Kupfer S; Erdmann E;
Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
[TBL] [Abstract][Full Text] [Related]
11. [Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients].
Scheen AJ; Lefèbvre PJ
Rev Med Liege; 2005 Nov; 60(11):896-901. PubMed ID: 16402538
[TBL] [Abstract][Full Text] [Related]
12. [Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)].
Nitschmann S
Internist (Berl); 2007 Jan; 48(1):89-90; discussion 90-1. PubMed ID: 17187243
[No Abstract] [Full Text] [Related]
13. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
[TBL] [Abstract][Full Text] [Related]
14. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.
Vallarino C; Perez A; Fusco G; Liang H; Bron M; Manne S; Joseph G; Yu S
Clin Drug Investig; 2013 Sep; 33(9):621-31. PubMed ID: 23881565
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
Zhu Z; Shen Z; Lu Y; Zhong S; Xu C
Diabetes Res Clin Pract; 2012 Oct; 98(1):159-63. PubMed ID: 22705039
[TBL] [Abstract][Full Text] [Related]
16. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
17. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population.
Doehner W; Erdmann E; Cairns R; Clark AL; Dormandy JA; Ferrannini E; Anker SD
Int J Cardiol; 2012 Dec; 162(1):20-6. PubMed ID: 22037349
[TBL] [Abstract][Full Text] [Related]
18. Redefining the role of thiazolidinediones in the management of type 2 diabetes.
Barnett AH
Vasc Health Risk Manag; 2009; 5(1):141-51. PubMed ID: 19436665
[TBL] [Abstract][Full Text] [Related]
19. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ
Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
